Mizuho reiterated their buy rating on shares of Horizon Pharma Inc. (NASDAQ:HZNP) in a research report report published on Tuesday. Mizuho currently has a $33.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the company. Brean Capital reaffirmed a buy rating and set a $30.00 target price on shares of Horizon Pharma in a research note on Tuesday, August 9th. Zacks Investment Research raised Horizon Pharma from a hold rating to a buy rating and set a $25.00 target price for the company in a research note on Wednesday, August 10th. Guggenheim reaffirmed a buy rating and set a $30.00 target price on shares of Horizon Pharma in a research note on Tuesday, August 23rd. BMO Capital Markets reaffirmed an outperform rating and set a $30.00 target price (up previously from $29.00) on shares of Horizon Pharma in a research note on Wednesday, August 10th. Finally, Piper Jaffray Cos. reaffirmed an overweight rating and set a $33.00 target price (down previously from $34.00) on shares of Horizon Pharma in a research note on Wednesday, August 10th. One analyst has rated the stock with a sell rating, three have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $30.00.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Shares of Horizon Pharma (NASDAQ:HZNP) opened at 18.25 on Tuesday. The company has a 50-day moving average of $18.92 and a 200 day moving average of $17.86. The firm’s market cap is $2.94 billion. Horizon Pharma has a one year low of $12.86 and a one year high of $23.70.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The company earned $257.40 million during the quarter, compared to analysts’ expectations of $235.43 million. During the same quarter in the prior year, the business posted $0.39 earnings per share. The company’s revenue for the quarter was up 48.9% compared to the same quarter last year. On average, equities research analysts expect that Horizon Pharma will post $2.15 EPS for the current fiscal year.

In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total value of $58,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Virginia Retirement System purchased a new stake in shares of Horizon Pharma during the first quarter worth approximately $282,000. Franklin Resources Inc. increased its position in Horizon Pharma by 5,195.9% in the first quarter. Franklin Resources Inc. now owns 1,276,730 shares of the biopharmaceutical company’s stock valued at $21,155,000 after buying an additional 1,252,622 shares during the period. BlackRock Group LTD increased its position in Horizon Pharma by 21.0% in the first quarter. BlackRock Group LTD now owns 100,919 shares of the biopharmaceutical company’s stock valued at $1,672,000 after buying an additional 17,505 shares during the period. BlackRock Fund Advisors increased its position in Horizon Pharma by 7.6% in the first quarter. BlackRock Fund Advisors now owns 2,937,687 shares of the biopharmaceutical company’s stock valued at $48,677,000 after buying an additional 208,391 shares during the period. Finally, BlackRock Institutional Trust Company N.A. increased its position in Horizon Pharma by 2.7% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,337,953 shares of the biopharmaceutical company’s stock valued at $38,740,000 after buying an additional 61,457 shares during the period. Institutional investors own 85.25% of the company’s stock.

About Horizon Pharma

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

5 Day Chart for NASDAQ:HZNP

Receive News & Stock Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related stocks with our FREE daily email newsletter.